Loading...

CDT CDT EQUITY INC Management Changes 8-K Filing

CDT

CDT

CDT EQUITY INC

(CDT)

2025 8-K

Equity Line Amendment

Reverse Stock Split

Stockholder Meeting Results

Funding Agreement Updates

Share Acquisition Agreement

Stock Purchase Agreement

Consulting Agreements

Share Sale Agreement

Stock Split Announcement

Financial Restatement Update

Reverse Stock Split

Reverse Stock Split

Appointment of New Auditor

Management Changes

License Agreement

Nasdaq Compliance

Nasdaq Compliance

Nasdaq Compliance

Nasdaq Compliance Issues

Stock Split Announcement

Nasdaq Delisting Notice

New Services Agreement

Convertible Notes Issued

Management Changes

Financial Restatement

Funding Agreement

Convertible Note Issuance

Annual Meeting Postponed

Nasdaq Compliance Issues

License Agreement with Astr...

Agreement with Nirland Limited

Amendment to Annual Meeting...

Annual Meeting Date and Sto...

Restatement of Financial St...

Business Combination

Business Combination

Special Meeting Results

Postponement of Special Mee...

Prospectus Supplement for S...

Special Meeting Scheduled

Asset Acquisitions

Merger Agreement Amendment

Promissory Note Issued

Amendment to Certificate of...

Special Meeting of Stockhol...

Merger Agreement and Subscr...

External Links:

On April 12, 2025, David Tapolczay resigned as CEO of Conduit Pharmaceuticals, and Andrew Regan was appointed as the new CEO on April 15, 2025; Faith Charles also resigned from the Board on April 16, 2025. Tapolczay will continue to work with the company in a new advisory role with a $240,000 salary and a $100,000 sign-on bonus.

AI Assistant

CDT EQUITY INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.